在大肠杆菌中Epoxomicin的异构表达
Sarah R Messenger1,2, David F Ackerley1,2, Mark J Calcott1,2
1School of Biological Sciences, Victoria University of Wellington, Wellington 6012, New Zealand.
ACS synthetic biology
|August 8, 2024
概括
研究人员对大肠杆菌进行了改造,以产生多发性骨髓瘤的蛋白酶体抑制剂epoxomicin. 通过优化基因表达来提高产量,为新型模拟开发铺平了道路.
科学领域:
- 生物技术是生物技术.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 埃博克索米辛是一种关键的环氧蛋白酶体抑制剂,用于多发性骨髓瘤治疗.
- 合成衍生物已被批准或正在接受癌症治疗的研究.
- 大肠杆菌作为生产epoxomicin和类似物的主体具有优势.
研究的目的:
- 为了工程大肠杆菌的生物合成的epoxomicin.
- 通过修改基因表达来优化环素的生产.
- 开发一个平台,用于创建改进的epoxomicin类似物.
主要方法:
- 在大肠杆菌 (Escherichia coli) 中表达了代码子优化的环氧生物合成基因 (epxD,epxE,epxF).
- 分析的产品,识别了epoxomicin和一个脱碳化子副产品.
- 优化了基因拷贝数量,并创建了一个epxE-epxF基因融合.
主要成果:
- 在工程化大肠杆菌中成功产生了epoxomicin.
- 主要产品是前体脱碳化过程中的子.
- 通过优化基因表达和融合,改善了epoxomicin的产量.
结论:
- 工程化大肠杆菌可以成为一个可行的宿主,用于epoxomicin生物合成.
- 优化的基因表达策略增强了epoxomicin的产量.
- 这一系统为开发新型环氧胺类同类物提供了基础.
相关概念视频
Antimicrobial Proteins
10.6K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
10.6K
Gram-negative Bacterial Protein Secretion Systems
1.7K
Gram-negative bacteria utilize sophisticated protein secretion systems to transport proteins across their double-membrane envelope into the extracellular environment or host cells. Based on their mechanism of action, these systems are classified into one-step and two-step pathways.One-Step Secretion Systems (Types I, III, IV, and VI)One-step secretion systems bypass the periplasm entirely, forming a continuous channel that spans both the inner and outer membranes:Type I Secretion System (T1SS):...
1.7K
Stringent Response in E. coli
526
Bacterial growth is closely tied to nutrient availability, with cells proliferating exponentially under favorable conditions and entering a stationary phase when resources become scarce. This transition is mediated by a regulatory mechanism known as the stringent response, which allows bacteria to adapt to nutrient deprivation by modulating gene expression and metabolic activity.During nutrient scarcity, intracellular amino acid levels decline. It results in the accumulation of uncharged tRNAs...
526
Development of Antibiotic Resistance
2.0K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
2.0K
Mechanism of Antibiotic Resistance in MRSA
215
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
215
Clinical Significance of Antibiotic Resistance
90
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
90


